Viridian Therapeutics, Inc.\DE — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-104.9% -$47M
$-93M
Free Cash Flow↓-110.5% -$126K
$-240K
Investing Cash Flow
$126M
Financing Cash Flow↑+1042.6% +$370M
$406M
Capex↑+110.5% +$126K
$240K
Stock-Based Comp↑+33.6% +$3M
$12M
Debt Issued
$29M
D&A↓-2.4% -$3K
$120K
SBC Allocated Expense↑+33.6% +$3M
$12M
SBC Unrecognized Cost
—